Products

EarlyTect (R) is the promise of Genomictree to keep your tomorrow healthy through early detection of cancer.
2
얼리텍
Bladder Cancer Detection

Qualitative detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients

Unmet needs
  • Hematuria is one of the most common symptoms in urinalysis encountered by urological practice and approximately 85% of BCa patients have hematuria.
  • In contrast, bladder cancer is found in only 5% to 20% of patients with micro or gross hematuria and in up to 60% of the patients with hematuria cause of bleeding is unknown.
  • Nevertheless, nearly all patients with hematuria are recommended performing cystoscopy because no criteria exists despite the existence of many different guidelines to analyze the cause of hematuria.
  • Thus ruling out hematuria patients with benign cause during primary evaluation is challenging. Bladder cancer is often diagnosed by cystoscopy with urine cytology as an adjunct. Cystoscopic examination is the most sensitive gold standard tool, which is an invasive procedure that is very expensive, very uncomfortable and not easy to perform.
  • Voided urine cytology is the most commonly used noninvasive standard method adjunct to cystoscopy for detecting transitional cell carcinoma and recurrence monitoring, while its sensitivity is known to be as low as 20% to 50%, especially for low-grade of BCa.
  • Therefore, development of molecular diagnostic markers with high accuracy in the evaluation of hematuria is required in order to reduce costs and to avoid highly invasive diagnostic procedures.
The solution EarlyTect® B to detect bladder cancer: under developing
  • Urine cell-based biomarker test with proven clinical sensitivity and specificity for bladder cancer.
  • It utilizes the general real time PCR Instrument Systems to measure genetic and epigenetic markers in 10 ml of voided urine samples.
  • This easy to use and fast solution requires less than 8 h of hands-on time, providing actionable results in real-time.
  • This test may help for discriminating of bladder cancer from hematuria patients.
Detection of Bladder Cancer Recurrence

Qualitative detection of genetic and epigenetic markers for diagnostics of recurrence in patients previously diagnosed with bladder cancer

Unmet needs
  • 75% of newly diagnosed bladder cancer is non-muscle invasive superficial bladder cancer and 52% of those patients had recurrence within 5 years.
  • A big challenge for the urologist is the detection of bladder cancer recurrence.
  • A fast, non-invasive test with high clinical performance, which is able to detect recurrence in bladder cancer patients is needed.
The solution EarlyTect® B to detect bladder cancer recurrence: under developing
  • Urine cell-based biomarker test with proven clinical sensitivity and specificity for bladder cancer recurrence.
  • It utilizes the general real time PCR Instrument Systems to measure genetic and epigenetic markers in 10 ml of voided urine samples.
  • This easy to use and fast solution requires less than 8 h of hands-on time, providing actionable results in real-time.
  • This test may help for detecting recurrence in patients previously diagnosed bladder cancer.
이미지
EarlyTect® Bladder Cancer
(Ongoing Pivotal Clinical Trial for Approval)
이미지

Cancer Type: Bladder Cancer (Early Detection)

Subject: Hematuria patients

Biomarker: PENK methylation

Specimen: Urine DNA (10mL)

Patent Granted: South Korea, US, Europe, China and Japan